11,211 results match your criteria Imaging in Small Cell Lung Cancer


Accuracy and Reproducibility of Endoscopic Ultrasound B-Mode Features for Observer-Based Lymph Nodal Malignancy Prediction.

Respiration 2021 Jun 24:1-9. Epub 2021 Jun 24.

Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Background: Endoscopic ultrasound routinely guides lymph node evaluation for the staging of a known or suspected lung cancer. Characteristics seen on B-mode imaging might help the observer decide on the lymph nodes of risk. The influence of nodal size on the predictivity of these characteristics and the agreement with which operators can combine these for malignancy risk prediction is to be determined. Read More

View Article and Full-Text PDF

Osteogenic and brain metastases after non-small cell lung cancer resection.

Int J Clin Oncol 2021 Jun 24. Epub 2021 Jun 24.

Division of Thoracic Surgery, Shizuoka Cancer Center, Shimonagakubo 1007, Nagaizumi-cho, Shunto-gun, Shizuoka, 411-8777, Japan.

Background: A significant number of non-small cell lung cancer (NSCLC) patients develop osteogenic metastases (OMs) and/or brain metastases (BMs) after surgery, however, routine chest computed tomography (CT) sometimes fails to diagnose these recurrences. We investigated the incidence of BMs and OMs after pulmonary resection and aimed to identify candidates who can benefit from brain magnetic resonance imaging (MRI) and F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in addition to CT.

Methods: We retrospectively reviewed medical records of 1099 NSCLC patients who underwent pulmonary resection between 2002 and 2013. Read More

View Article and Full-Text PDF

Radiotherapy of brain metastasis from lung cancer in limited resource settings.

J Thorac Dis 2021 May;13(5):3308-3314

Department of Radiation Oncology, Tata Memorial centre, Homi Bhabha National Institute, Mumbai, India.

Radiotherapy is one of the most commonly used treatment modality for brain metastases from lung cancer. Its use has evolved from conventional whole brain radiation therapy (WBRT) to more sophisticated stereotactic radiosurgery (SRS) and hippocampal sparing radiotherapy. Indications of cranial radiotherapy are also evolving with the advent of targeted therapies directed against molecular markers like epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Read More

View Article and Full-Text PDF

Local ablative therapy of brain metastasis from non-small cell lung cancer: benefits and limitations.

J Thorac Dis 2021 May;13(5):3289-3294

Department of Radiation Oncology, AC Camargo Cancer Center, São Paulo, Brazil.

Brain metastases (BMs) are the most common intracranial tumors and non-small cell lung cancer (NSCLC) are responsible for BM more than any other solid tumor. Its frequency is increasing due to of the availability of new imaging techniques, earlier diagnosis and improvement in treatment techniques and survival rates. NSCLC patients with BM represent heterogeneous prognostic group. Read More

View Article and Full-Text PDF

Prophylactic cranial irradiation confers favourable prognosis for patients with limited-stage small cell lung cancer in the era of MRI: A propensity score-matched analysis.

J Med Imaging Radiat Oncol 2021 Jun 22. Epub 2021 Jun 22.

Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Introduction: Prophylactic cranial irradiation (PCI) is recommended for patients with limited-stage small cell lung cancer (LS-SCLC) who achieve good response after chemoradiotherapy. But PCI is neurotoxic. Magnetic resonance imaging (MRI) is the standard tool for evaluating brain metastasis (BM). Read More

View Article and Full-Text PDF

Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.

Chin J Cancer Res 2021 Apr;33(2):203-215

Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.

Immune checkpoint inhibitors (ICIs), a type of immunotherapy, have become one of the most important therapeutic options for first- and second-line treatment of advanced non-small cell lung cancer (NSCLC). Recent clinical studies have shown that immunotherapy can offer substantial survival benefits to patients with early-stage or resectable advanced NSCLC. However, considering the importance of timing when using ICIs and their associated adverse events (AEs), the advantages and disadvantages of using these agents need to be weighed carefully when deciding the use of a combined treatment. Read More

View Article and Full-Text PDF

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.

Oncogene 2021 Jun 21. Epub 2021 Jun 21.

Center for Molecular Medicine, Research Center for Cancer Biology, and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.

The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Read More

View Article and Full-Text PDF

Non-bacterial thrombotic endocarditis and coronary thrombectomy in a patient with metastatic small cell lung carcinoma.

BMJ Case Rep 2021 Jun 21;14(6). Epub 2021 Jun 21.

Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.

A 66-year-old Caucasian man was initially admitted with a metastatic small cell lung carcinoma, hyponatraemia and obstructive pneumonia. His transthoracic echocardiogram (TTE) was normal. Ten days after admission, he was diagnosed with a non-ST segment elevation myocardial infarction (MI). Read More

View Article and Full-Text PDF

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer.

JCO Precis Oncol 2021 Jan 1;5:325-332. Epub 2021 Feb 1.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

For patients with surgically resected disease, multiple studies suggest a benefit of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in delaying cancer recurrence. The necessary duration of therapy for benefit is unknown.

Materials And Methods: This randomized phase II study enrolled patients with completely resected stage IA-IIIB -mutant non-small-cell lung cancer (American Joint Committee on Cancer 7th edition) after stage-appropriate standard-of-care adjuvant therapy. Read More

View Article and Full-Text PDF
January 2021

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.

Intern Med 2021 Jun 19. Epub 2021 Jun 19.

Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.

Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 64 -year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Read More

View Article and Full-Text PDF

targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand.

Mol Ther Methods Clin Dev 2021 Jun 24;21:670-680. Epub 2021 Apr 24.

Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Despite their exceptional capacity for transgene delivery , lentiviral (LV) vectors have been slow to demonstrate clinical utility in the context of applications. Unresolved safety concerns related to broad LV vector tropism have limited LV vectors to applications. Here, we report on a novel LV vector-pseudotyping strategy involving envelope glycoproteins of Tupaia paramyxovirus (TPMV) engineered to specifically target human cell-surface receptors. Read More

View Article and Full-Text PDF

Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma.

Mol Ther Nucleic Acids 2021 Sep 1;25:1-10. Epub 2021 May 1.

Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.

Lung adenocarcinoma (LUAD), the most common histological type of non-small cell lung cancer, is one of the most malignant and deadly diseases. Current treatments for advanced LUAD patients are far from ideal and require further improvements. Here, we utilized a systematic integrative analysis of LUAD microRNA sequencing (miRNA-seq) and RNA-seq data from The Cancer Genome Atlas (TCGA) to identify clinically relevant tumor suppressor miRNAs. Read More

View Article and Full-Text PDF
September 2021

Clinical value of FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer.

Urol Oncol 2021 Jun 14. Epub 2021 Jun 14.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Objective: Metastatic bladder cancer is an aggressive disease that can often be difficult to diagnose and stage with conventional cross-sectional imaging. The primary objective of this study was to determine the clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-FDG) PET/MRI for surveillance and restaging of patients with muscle-invasive, locally advanced, and metastatic bladder cancer compared to conventional imaging methods.

Materials And Methods: This retrospective study enrolled patients with muscle-invasive, locally advanced and metastatic bladder cancer in a single institute evaluated with F-FDG PET/MRI. Read More

View Article and Full-Text PDF

Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.

PLoS One 2021 17;16(6):e0252950. Epub 2021 Jun 17.

Comparative Medicine, Pfizer Inc., La Jolla, CA, United States of America.

Unlike the majority of cancers, survival for lung cancer has not shown much improvement since the early 1970s and survival rates remain low. Genetically engineered mice tumor models are of high translational relevance as we can generate tissue specific mutations which are observed in lung cancer patients. Since these tumors cannot be detected and quantified by traditional methods, we use micro-computed tomography imaging for longitudinal evaluation and to measure response to therapy. Read More

View Article and Full-Text PDF

Circular RNAs Are Promising Biomarkers in Liquid Biopsy for the Diagnosis of Non-small Cell Lung Cancer.

Front Mol Biosci 2021 31;8:625722. Epub 2021 May 31.

Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.

The high incidence and mortality of lung cancer make early detection of lung cancer particularly important. At present, the diagnosis of lung cancer mainly depends on diagnostic imaging and tissue biopsy. However, current diagnostics are not satisfactory owing to the low specificity and inability of multiple sampling. Read More

View Article and Full-Text PDF

Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.

J Immunother Cancer 2021 Jun;9(6)

Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA

Background: Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand 1 (PD-L1) expression status determined by immunohistochemistry (IHC) of biopsies is the only clinically approved companion biomarker to trigger the use of ICI therapy. Based on prior work showing a relationship between quantitative imaging and gene expression, we hypothesize that quantitative imaging (radiomics) can provide an alternative surrogate for PD-L1 expression status in clinical decision support. Read More

View Article and Full-Text PDF

[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone].

Zhongguo Fei Ai Za Zhi 2021 Jun 17. Epub 2021 Jun 17.

Department of Stereotactic Radiotherapy, Qingdao Central Hospital, Qingdao 266042, China.

Background: Immune checkpoint inhibitor associated pneumonia (CIP) is a serious side effect of immune checkpoint inhibitors. There is a consensus on the treatment of acute phase of CIP, but the treatment of pulmonary interstitial fibrosis after the acute phase is still a clinical problem to be solved.

Methods: The diagnosis and treatment of a non-small cell lung cancer (NSCLC) patient with immune checkpoint inhibitor associated pneumonia in the Stereotactic Radiotherapy Department of Qingdao Central Hospital were retrospectively analyzed, and literatures were reviewed. Read More

View Article and Full-Text PDF

[Tc]Tc-Galacto-RGD integrin αβ-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data.

EJNMMI Res 2021 Jun 13;11(1):59. Epub 2021 Jun 13.

Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) are beneficial in patients with lung cancer. We explored the clinical value of [Tc]Tc-Galacto-RGD single-photon emission computed tomography (SPECT/CT) in patients with lung cancer, integrin αβ expression, and neovascularization in lung cancer subtypes was also addressed.

Methods: A total of 185 patients with lung cancer and 25 patients with benign lung diseases were enrolled in this prospective study from January 2013 to December 2016. Read More

View Article and Full-Text PDF

Exploration of spatial distribution of brain metastasis from small cell lung cancer and identification of metastatic risk level of brain regions: a multicenter, retrospective study.

Cancer Imaging 2021 Jun 13;21(1):41. Epub 2021 Jun 13.

Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, 88 Keling Road, Suzhou New District, Suzhou, 215163, Jiangsu, China.

Objectives: This study aimed to explore the spatial distribution of brain metastases (BMs) from small cell lung cancer (SCLC) a homogenous sample, and to identify the metastatic risk levels in brain regions.

Methods: T1-enhanced magnetic resonance imaging (MRI) from SCLC patients were retrospectively reviewed from three medical institutions in China. All images were registered to the standard brain template provided by the Montreal Neurological Institute (MNI) 152 database, followed by transformation of the location of all BMs to the space of standard brain. Read More

View Article and Full-Text PDF

Mass spectrometry imaging of L-[ring-C]-labeled phenylalanine and tyrosine kinetics in non-small cell lung carcinoma.

Cancer Metab 2021 Jun 11;9(1):26. Epub 2021 Jun 11.

Maastricht MultiModal Molecular Imaging institute (M4I), Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.

Background: Metabolic reprogramming is a common phenomenon in tumorigenesis and tumor progression. Amino acids are important mediators in cancer metabolism, and their kinetics in tumor tissue are far from being understood completely. Mass spectrometry imaging is capable to spatiotemporally trace important endogenous metabolites in biological tissue specimens. Read More

View Article and Full-Text PDF

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.

Medicine (Baltimore) 2021 Jun;100(23):e25774

Division of Medical Oncology, Department of Medicine, Showa University School of Medicine.

Introduction: Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop. Here, we describe a severe case of sclerosing cholangitis-like irAE. We report the use of 3 immunosuppressive agents that resulted in the death of the patient due to treatment inefficacy. Read More

View Article and Full-Text PDF

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers.

Front Oncol 2021 24;11:674731. Epub 2021 May 24.

Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Introduction: The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy (SBRT).

Methods: All inoperable, early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy (SBRT) from 2014-2017 were included in this single-centre study. They were followed regularly for 12 months after treatment. Read More

View Article and Full-Text PDF

Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism.

Ann Lab Med 2021 Nov;41(6):521-531

Endocrinology Unit, Department of Medicine (DIMED), University-Hospital of Padova, Padova, Italy.

Cushing's syndrome (CS) is a rare disease caused by chronic and excessive cortisol secretion. When adrenocorticotropin hormone (ACTH) is measurable, autonomous adrenal cortisol secretion could be reasonably ruled out in a differential diagnosis of CS. ACTH-dependent CS accounts for 80%-85% of cases and involves cortisol production stimulated by uncontrolled pituitary or ectopic ACTH secretion. Read More

View Article and Full-Text PDF
November 2021

EGFR-mutant NSCLC presenting with stroke and massive systemic embolization as the first manifestation: case report.

BMC Neurol 2021 Jun 9;21(1):221. Epub 2021 Jun 9.

Department of Neurology, The Second Hospital of Hebei Medical University, 309 Zhonghuabei Street, Hebei, 050000, Shijiazhuang, People's Republic of China.

Background: Presentation with massive systemic embolization as the initial manifestation of occult malignancy is infrequent. The standard management of cancer-related arterial thromboembolism has not yet been established.

Case Presentation: We described a case of Trousseau's syndrome resulting in acute ischemic stroke concomitant with multiple embolizations in the spleen and kidney during oral administration of dabigatran for pulmonary embolism preceding the diagnosis of a malignant tumor. Read More

View Article and Full-Text PDF

Preoperative pectoralis muscle radiodensity as a risk factor for postoperative complications after thoracoscopic lobectomy for non-small cell lung cancer.

Ann Palliat Med 2021 May;10(5):5444-5454

Department of Thoracic Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

Background: Skeletal muscle radiodensity is associated with postoperative complications in cancer. However, data on skeletal muscle radiodensity and postoperative complication risk in patients with non-small cell lung cancer (NSCLC) are scarce, and this study investigated the relationship between skeletal muscle radiodensity and postoperative complication risk in patients with NSCLC treated by thoracoscopic lobectomy.

Methods: Quantitative and qualitative measurements of the pectoralis muscle were performed on a single axial slice above the aortic arch in the precontrast computed tomography (CT) scan performed before surgery. Read More

View Article and Full-Text PDF

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.

J Clin Transl Res 2021 Apr 16;7(2):185-198. Epub 2021 Apr 16.

Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, C/Diego de Velázquez, 1, 28223, Pozuelo de Alarcón, Madrid, Spain.

Background And Aim: In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. Read More

View Article and Full-Text PDF

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.

Sci Rep 2021 Jun 8;11(1):12084. Epub 2021 Jun 8.

Institute of Biomedical Sciences, National Chung Hsing University, No. 145, Xingda Rd., South Dist., Taichung, 402, Taiwan.

The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC patients with gefitinib, erlotinib or afatinib as first-line EGFR-TKIs treatment for analysis. 373 patients received re-biopsies after progressive disease to first-line EGFR-TKIs treatment, and the total positive rate of T790M was 51. Read More

View Article and Full-Text PDF

Can F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis.

BMJ Open 2021 06 8;11(6):e044313. Epub 2021 Jun 8.

Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China

Objectives: This study aimed to explore the diagnostic significance of F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor () mutations in patients with non-small cell lung cancer (NSCLC).

Design: A systematic review and meta-analysis.

Data Sources: The PubMed, EMBASE and Cochrane library databases were searched from the earliest available date to December 2020. Read More

View Article and Full-Text PDF

Post-immunotherapy imaging in lung cancer.

Clin Radiol 2021 Jun 5. Epub 2021 Jun 5.

The University of Texas MD Anderson Cancer Center, Thoracic Imaging, 1515 Holcombe Blvd. Unit 1478, Houston, TX 77030, USA.

By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events. Read More

View Article and Full-Text PDF

Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.

BMC Med Imaging 2021 Jun 7;21(1):96. Epub 2021 Jun 7.

Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.

Objective: To assess the ablative margin of microwave ablation (MWA) for stage I non-small cell lung cancer (NSCLC) using a three-dimensional (3D) reconstruction technique.

Materials And Methods: We retrospectively analyzed 36 patients with stage I NSCLC lesions undergoing MWA and analyzed the relationship between minimal ablative margin and the local tumor progression (LTP) interval, the distant metastasis interval and disease-free survival (DFS). The minimal ablative margin was measured using the fusion of 3D computed tomography reconstruction technique. Read More

View Article and Full-Text PDF